PortfoliosLab logoPortfoliosLab logo
BBC vs. GNOM
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

BBC vs. GNOM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Global X Genomics & Biotechnology ETF (GNOM). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

The year-to-date returns for both investments are quite close, with BBC having a 11.41% return and GNOM slightly higher at 11.56%.


BBC

1D
2.55%
1M
-4.36%
YTD
11.41%
6M
14.39%
1Y
123.10%
3Y*
20.63%
5Y*
-1.47%
10Y*
7.73%

GNOM

1D
3.47%
1M
11.33%
YTD
11.56%
6M
9.34%
1Y
57.90%
3Y*
0.45%
5Y*
-9.59%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

BBC vs. GNOM - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
BBC
Virtus LifeSci Biotech Clinical Trials ETF
11.41%63.77%-1.11%-1.80%-35.13%-22.31%30.32%29.80%
GNOM
Global X Genomics & Biotechnology ETF
11.56%18.65%-15.99%-8.63%-36.27%-15.93%51.52%1.56%

Correlation

The correlation between BBC and GNOM is 0.79, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.79

Correlation (3Y)
Calculated over the trailing 3-year period

0.83

Correlation (5Y)
Calculated over the trailing 5-year period

0.85

Correlation (All Time)
Calculated using the full available price history since Apr 11, 2019

0.85

The correlation between BBC and GNOM has been stable across timeframes, ranging from 0.79 to 0.85 - a consistent structural relationship.

BBC vs. GNOM - Sectors Allocation Comparison


Sectors
BBC
GNOM

Healthcare

100.0%
99.6%

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Financial Services

-

-

Industrials

-

-

Real Estate

-

-

Technology

-

0.4%

Utilities

-

-

Healthcare

BBC
100.0%
GNOM
99.6%

Basic Materials

BBC

-

GNOM

-

Communication Services

BBC

-

GNOM

-

Consumer Cyclical

BBC

-

GNOM

-

Consumer Defensive

BBC

-

GNOM

-

Energy

BBC

-

GNOM

-

Financial Services

BBC

-

GNOM

-

Industrials

BBC

-

GNOM

-

Real Estate

BBC

-

GNOM

-

Technology

BBC

-

GNOM
0.4%

Utilities

BBC

-

GNOM

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

BBC vs. GNOM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BBC
BBC Risk / Return Rank: 9191
Overall Rank
BBC Sharpe Ratio Rank: 9494
Sharpe Ratio Rank
BBC Sortino Ratio Rank: 9090
Sortino Ratio Rank
BBC Omega Ratio Rank: 8181
Omega Ratio Rank
BBC Calmar Ratio Rank: 9595
Calmar Ratio Rank
BBC Martin Ratio Rank: 9494
Martin Ratio Rank

GNOM
GNOM Risk / Return Rank: 6262
Overall Rank
GNOM Sharpe Ratio Rank: 6767
Sharpe Ratio Rank
GNOM Sortino Ratio Rank: 6868
Sortino Ratio Rank
GNOM Omega Ratio Rank: 5858
Omega Ratio Rank
GNOM Calmar Ratio Rank: 6666
Calmar Ratio Rank
GNOM Martin Ratio Rank: 5454
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BBC vs. GNOM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Global X Genomics & Biotechnology ETF (GNOM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


BBCGNOMDifference
Sharpe ratioReturn per unit of total volatility

+1.31

Sortino ratioReturn per unit of downside risk

+1.06

Omega ratioGain probability vs. loss probability

1.48

1.35

+0.13

Calmar ratioReturn relative to maximum drawdown

8.20

3.20

+5.00

Martin ratioReturn relative to average drawdown

25.91

9.21

+16.70

BBC vs. GNOM - Sharpe Ratio Comparison

The current BBC Sharpe Ratio is 3.49, which is higher than the GNOM Sharpe Ratio of 2.18. The chart below compares the historical Sharpe Ratios of BBC and GNOM, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


BBCGNOMDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

3.49

2.18

+1.31

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.04

-0.29

+0.25

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.21

Sharpe Ratio (All Time)

Calculated using the full available price history

0.12

-0.07

+0.20

Drawdowns

BBC vs. GNOM - Drawdown Comparison

The maximum BBC drawdown since its inception was -76.85%, roughly equal to the maximum GNOM drawdown of -75.00%. Use the drawdown chart below to compare losses from any high point for BBC and GNOM.


Loading charts...

Drawdown Indicators


BBCGNOMDifference

Max Drawdown

Largest peak-to-trough decline

-76.85%

-75.00%

-1.85%

Max Drawdown (1Y)

Largest decline over 1 year

-15.10%

-18.17%

+3.07%

Max Drawdown (3Y)

Largest decline over 3 years

-54.45%

-46.47%

-7.98%

Max Drawdown (5Y)

Largest decline over 5 years

-72.44%

-72.29%

-0.15%

Max Drawdown (10Y)

Largest decline over 10 years

-76.85%

Current Drawdown

Current decline from peak

-28.49%

-53.90%

+25.41%

Average Drawdown

Average peak-to-trough decline

-37.13%

-40.56%

+3.43%

Ulcer Index

Depth and duration of drawdowns from previous peaks

4.77%

6.30%

-1.53%

Volatility

BBC vs. GNOM - Volatility Comparison

Virtus LifeSci Biotech Clinical Trials ETF (BBC) has a higher volatility of 11.28% compared to Global X Genomics & Biotechnology ETF (GNOM) at 8.77%. This indicates that BBC's price experiences larger fluctuations and is considered to be riskier than GNOM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


BBCGNOMDifference

Volatility (1M)

Calculated over the trailing 1-month period

11.28%

8.77%

+2.51%

Volatility (6M)

Calculated over the trailing 6-month period

26.27%

19.72%

+6.55%

Volatility (1Y)

Calculated over the trailing 1-year period

35.44%

26.66%

+8.78%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

39.32%

33.61%

+5.71%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

37.74%

34.19%

+3.55%

BBC vs. GNOM - Expense Ratio Comparison

BBC has a 0.79% expense ratio, which is higher than GNOM's 0.50% expense ratio.


Dividends

BBC vs. GNOM - Dividend Comparison

BBC's dividend yield for the trailing twelve months is around 1.53%, more than GNOM's 1.23% yield.


PositionTTM20252024202320222021202020192018201720162015
BBC
Virtus LifeSci Biotech Clinical Trials ETF
1.53%1.70%1.00%0.34%0.00%0.00%0.00%0.00%0.00%2.09%0.00%0.51%
GNOM
Global X Genomics & Biotechnology ETF
1.23%1.37%0.00%0.00%0.00%0.03%0.14%0.00%0.00%0.00%0.00%0.00%

Frequently Asked Questions


BBC and GNOM have a correlation of 0.79, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

BBC has higher volatility (11.28%) compared to GNOM (8.77%). In terms of maximum drawdown, BBC dropped -76.85% vs GNOM's -75.00%.

On 5-year performance, BBC leads with -1.47% vs -9.59% for GNOM. On fees, GNOM is cheaper at 0.50% per year. On volatility, GNOM has been the lower-risk option at 8.77%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 5-year period, BBC has performed better with a -1.47% return vs -9.59%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

GNOM is cheaper with a 0.50% expense ratio, compared with 0.79% for BBC.

BBC has the higher dividend yield at 1.53%, compared with 1.23% for GNOM.

BBC tracks LifeSci Biotechnology Clinical Trials Index, while GNOM tracks Solactive Genomics Index. They also come from different issuers: Virtus Investment Partners and Global X. Their fees differ too: 0.79% for BBC and 0.50% for GNOM.

BBC currently has the higher Sharpe Ratio (3.49 vs 2.18), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for BBC and GNOM

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer